IS8390A - Use of gaboxadol in the treatment of insomnia - Google Patents

Use of gaboxadol in the treatment of insomnia

Info

Publication number
IS8390A
IS8390A IS8390A IS8390A IS8390A IS 8390 A IS8390 A IS 8390A IS 8390 A IS8390 A IS 8390A IS 8390 A IS8390 A IS 8390A IS 8390 A IS8390 A IS 8390A
Authority
IS
Iceland
Prior art keywords
gaboxadol
insomnia
treatment
Prior art date
Application number
IS8390A
Other languages
Icelandic (is)
Inventor
Ebert Bjarke
Lundahl Jonas
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8390(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of IS8390A publication Critical patent/IS8390A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
IS8390A 2003-12-18 2006-03-30 Use of gaboxadol in the treatment of insomnia IS8390A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301877 2003-12-18
PCT/DK2004/000861 WO2005058313A1 (en) 2003-12-18 2004-12-14 Use of gaboxadol for treating insomnia

Publications (1)

Publication Number Publication Date
IS8390A true IS8390A (en) 2006-03-30

Family

ID=34684447

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8390A IS8390A (en) 2003-12-18 2006-03-30 Use of gaboxadol in the treatment of insomnia

Country Status (17)

Country Link
EP (1) EP1720547A1 (en)
JP (1) JP2007515415A (en)
KR (1) KR20060103335A (en)
CN (1) CN1893942A (en)
AR (1) AR047154A1 (en)
AU (1) AU2004298313A1 (en)
BR (1) BRPI0415893A (en)
CA (1) CA2550610A1 (en)
EA (1) EA200600989A1 (en)
IL (1) IL176239A0 (en)
IS (1) IS8390A (en)
MX (1) MXPA06006685A (en)
NO (1) NO20063320L (en)
SG (1) SG133601A1 (en)
TW (1) TW200528098A (en)
WO (1) WO2005058313A1 (en)
ZA (1) ZA200602762B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
EP1906953A4 (en) * 2005-04-29 2009-05-20 Lundbeck & Co As H Acid and base salt forms of gaboxadol
MX2020002741A (en) * 2017-09-12 2020-07-21 Ovid Therapeutics Inc Use of gaboxadol in the treatment of narcolepsy.
JP2022501384A (en) 2018-09-20 2022-01-06 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. Use of gaboxador for the treatment of Tourette's syndrome, tics and stuttering
CA3123876A1 (en) * 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
JP2023507764A (en) 2019-12-18 2023-02-27 オービッド・セラピューティクス・インコーポレイテッド Gaboxadol for therapeutic treatment of 1p36 deletion syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525598C2 (en) * 1995-07-13 1997-09-25 Max Planck Gesellschaft sleeping pills
AR033896A1 (en) * 2001-05-21 2004-01-07 Lundbeck & Co As H GABOXADOL GRANULATED PREPARATIONS.

Also Published As

Publication number Publication date
CA2550610A1 (en) 2005-06-30
EA200600989A1 (en) 2006-10-27
CN1893942A (en) 2007-01-10
AR047154A1 (en) 2006-01-11
SG133601A1 (en) 2007-07-30
WO2005058313A1 (en) 2005-06-30
JP2007515415A (en) 2007-06-14
ZA200602762B (en) 2007-06-27
BRPI0415893A (en) 2007-01-09
KR20060103335A (en) 2006-09-28
EP1720547A1 (en) 2006-11-15
NO20063320L (en) 2006-07-18
AU2004298313A1 (en) 2005-06-30
TW200528098A (en) 2005-09-01
MXPA06006685A (en) 2006-08-23
IL176239A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
IL172316A0 (en) Novel compounds and their use in therapy
DK1636139T3 (en) Water Treatment Facilities
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
DE60319810D1 (en) ANSCHWEMMFILTERMEDIEN AND MANUFACTURING AND USE PROCESS
DE60315135D1 (en) therapy probe
IL180078A (en) 9-cis-retinal derivative for use in the treatment of 11-cis -retinal deficiency
EE200500035A (en) Personal therapy section
GB0324761D0 (en) Use of compounds in therapy
IS7348A (en) N-pyrazinyl-phenylsulfonamide and their use in the treatment of cerebrovascular diseases
IS8072A (en) Cholesterol transfer agents in the treatment of hypercholesterolemia
IS7825A (en) Therapeutic treatment
NO20050689L (en) Therapeutic use
DK1678085T3 (en) Fluid treatment
IS7444A (en) Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases
IS8390A (en) Use of gaboxadol in the treatment of insomnia
DK1670482T4 (en) USE OF CICLESONIDE IN THE TREATMENT OF RESPIRATORY DISEASES
NO20055517D0 (en) 4-, 6-O 7-hydroxyindoles with N-oxide groups and their use as therapeutic agents
ATA13602003A (en) THERAPEUTIC TREATMENT DEVICE
ITMI20030647A1 (en) DEVICE FOR THE TREATMENT OF BLOOD IN EXTRACORPOREA CIRCULATION
ATE442835T1 (en) SURFACE TREATMENT
IS7868A (en) Use of corticoliberin-urocortin system in the treatment of inflammatory diseases.
DK1496918T3 (en) USE OF SODIUM METHAARSENITE IN THE TREATMENT OF TUMORS
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
IS8391A (en) Use of siramine in the treatment of cancer
DK1680405T3 (en) Bengamide derivatives and their use in the treatment of cancer diseases